268 related articles for article (PubMed ID: 20212451)
1. Rhabdoid tumor: gene expression clues to pathogenesis and potential therapeutic targets.
Gadd S; Sredni ST; Huang CC; Perlman EJ;
Lab Invest; 2010 May; 90(5):724-38. PubMed ID: 20212451
[TBL] [Abstract][Full Text] [Related]
2. Imprinted CDKN1C is a tumor suppressor in rhabdoid tumor and activated by restoration of SMARCB1 and histone deacetylase inhibitors.
Algar EM; Muscat A; Dagar V; Rickert C; Chow CW; Biegel JA; Ekert PG; Saffery R; Craig J; Johnstone RW; Ashley DM
PLoS One; 2009; 4(2):e4482. PubMed ID: 19221586
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms by which SMARCB1 loss drives rhabdoid tumor growth.
Kim KH; Roberts CW
Cancer Genet; 2014 Sep; 207(9):365-72. PubMed ID: 24853101
[TBL] [Abstract][Full Text] [Related]
4. Differential microRNA expression profiles between malignant rhabdoid tumor and epithelioid sarcoma: miR193a-5p is suggested to downregulate SMARCB1 mRNA expression.
Kohashi K; Yamamoto H; Kumagai R; Yamada Y; Hotokebuchi Y; Taguchi T; Iwamoto Y; Oda Y
Mod Pathol; 2014 Jun; 27(6):832-9. PubMed ID: 24287458
[TBL] [Abstract][Full Text] [Related]
5. SNF5 reexpression in malignant rhabdoid tumors regulates transcription of target genes by recruitment of SWI/SNF complexes and RNAPII to the transcription start site of their promoters.
Kuwahara Y; Wei D; Durand J; Weissman BE
Mol Cancer Res; 2013 Mar; 11(3):251-60. PubMed ID: 23364536
[TBL] [Abstract][Full Text] [Related]
6. Nonsense mutation and inactivation of SMARCA4 (BRG1) in an atypical teratoid/rhabdoid tumor showing retained SMARCB1 (INI1) expression.
Hasselblatt M; Gesk S; Oyen F; Rossi S; Viscardi E; Giangaspero F; Giannini C; Judkins AR; Frühwald MC; Obser T; Schneppenheim R; Siebert R; Paulus W
Am J Surg Pathol; 2011 Jun; 35(6):933-5. PubMed ID: 21566516
[TBL] [Abstract][Full Text] [Related]
7. Rhabdoid tumor predisposition syndrome.
Sredni ST; Tomita T
Pediatr Dev Pathol; 2015; 18(1):49-58. PubMed ID: 25494491
[TBL] [Abstract][Full Text] [Related]
8. Aurora A is a repressed effector target of the chromatin remodeling protein INI1/hSNF5 required for rhabdoid tumor cell survival.
Lee S; Cimica V; Ramachandra N; Zagzag D; Kalpana GV
Cancer Res; 2011 May; 71(9):3225-35. PubMed ID: 21521802
[TBL] [Abstract][Full Text] [Related]
9. Rhabdoid tumor predisposition syndrome caused by SMARCB1 constitutional deletion: prenatal detection of new case of recurrence in siblings due to gonadal mosaicism.
Gigante L; Paganini I; Frontali M; Ciabattoni S; Sangiuolo FC; Papi L
Fam Cancer; 2016 Jan; 15(1):123-6. PubMed ID: 26342593
[TBL] [Abstract][Full Text] [Related]
10. Frequent co-inactivation of the SWI/SNF subunits SMARCB1, SMARCA2 and PBRM1 in malignant rhabdoid tumours.
Rao Q; Xia QY; Wang ZY; Li L; Shen Q; Shi SS; Wang X; Liu B; Wang YF; Shi QL; Ma HH; Lu ZF; He Y; Zhang RS; Yu B; Zhou XJ
Histopathology; 2015 Jul; 67(1):121-9. PubMed ID: 25496315
[TBL] [Abstract][Full Text] [Related]
11. Loss of IGFBP7 expression and persistent AKT activation contribute to SMARCB1/Snf5-mediated tumorigenesis.
Darr J; Klochendler A; Isaac S; Eden A
Oncogene; 2014 Jun; 33(23):3024-32. PubMed ID: 23851500
[TBL] [Abstract][Full Text] [Related]
12. Rhabdoid tumors: an initial clue to the role of chromatin remodeling in cancer.
Lee RS; Roberts CW
Brain Pathol; 2013 Mar; 23(2):200-5. PubMed ID: 23432645
[TBL] [Abstract][Full Text] [Related]
13. Non-linkage of familial rhabdoid tumors to SMARCB1 implies a second locus for the rhabdoid tumor predisposition syndrome.
Frühwald MC; Hasselblatt M; Wirth S; Köhler G; Schneppenheim R; Subero JI; Siebert R; Kordes U; Jürgens H; Vormoor J
Pediatr Blood Cancer; 2006 Sep; 47(3):273-8. PubMed ID: 16206192
[TBL] [Abstract][Full Text] [Related]
14. SNF5/INI1 deficiency redefines chromatin remodeling complex composition during tumor development.
Wei D; Goldfarb D; Song S; Cannon C; Yan F; Sakellariou-Thompson D; Emanuele M; Major MB; Weissman BE; Kuwahara Y
Mol Cancer Res; 2014 Nov; 12(11):1574-85. PubMed ID: 25009291
[TBL] [Abstract][Full Text] [Related]
15. Phosphoproteomic analysis reveals Smarcb1 dependent EGFR signaling in Malignant Rhabdoid tumor cells.
Darr J; Klochendler A; Isaac S; Geiger T; Eden A
Mol Cancer; 2015 Sep; 14():167. PubMed ID: 26370283
[TBL] [Abstract][Full Text] [Related]
16. Biology and Treatment of Rhabdoid Tumor.
Geller JI; Roth JJ; Biegel JA
Crit Rev Oncog; 2015; 20(3-4):199-216. PubMed ID: 26349416
[TBL] [Abstract][Full Text] [Related]
17. Premature termination of SMARCB1 translation may be followed by reinitiation in schwannomatosis-associated schwannomas, but results in absence of SMARCB1 expression in rhabdoid tumors.
Hulsebos TJ; Kenter S; Verhagen WI; Baas F; Flucke U; Wesseling P
Acta Neuropathol; 2014 Sep; 128(3):439-48. PubMed ID: 24740647
[TBL] [Abstract][Full Text] [Related]
18. SMARCB1 deletion by a complex three-way chromosomal translocation in an extrarenal malignant rhabdoid tumor.
Bahrami A; Lee S; Caradine KD; Raimondi SC; Folpe AL
Cancer Genet; 2014 Sep; 207(9):437-40. PubMed ID: 25312828
[TBL] [Abstract][Full Text] [Related]
19. Infrequent SMARCB1/INI1 gene alteration in epithelioid sarcoma: a useful tool in distinguishing epithelioid sarcoma from malignant rhabdoid tumor.
Kohashi K; Izumi T; Oda Y; Yamamoto H; Tamiya S; Taguchi T; Iwamoto Y; Hasegawa T; Tsuneyoshi M
Hum Pathol; 2009 Mar; 40(3):349-55. PubMed ID: 18973917
[TBL] [Abstract][Full Text] [Related]
20. SMARCB1 deficiency in tumors from the peripheral nervous system: a link between schwannomas and rhabdoid tumors?
Rizzo D; Fréneaux P; Brisse H; Louvrier C; Lequin D; Nicolas A; Ranchère D; Verkarre V; Jouvet A; Dufour C; Edan C; Stéphan JL; Orbach D; Sarnacki S; Pierron G; Parfait B; Peuchmaur M; Delattre O; Bourdeaut F
Am J Surg Pathol; 2012 Jul; 36(7):964-72. PubMed ID: 22614000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
